期刊文献+

2型糖尿病24 h尿钠排泄与脂代谢关系研究 被引量:8

Relationship between 24-h urinary sodium and lipid metabolism in patients with type 2 diabetes
原文传递
导出
摘要 目的探讨2型糖尿病患者24h尿钠与脂代谢的关系。方法收集2012年9月至2013年7月第三军医大学大坪医院200例2型糖尿病住院患者一般资料,测定血脂、空腹血糖、24h尿钠等生化指标。采用单因素方差分析、Logistic回归分析等方法分析尿钠排泄与脂代谢的关系。结果按24h尿钠四分位数分为低尿钠组、中尿钠组、中高尿钠组、高尿钠组,四组三酰甘油呈逐渐增高趋势,高尿钠组三酰甘油[1.87mmol/L(1.24~3.93mm01/L)]显著高于低尿钠组[1.43mmol/L(1.13—2.20mmol/L),P=0.015],Logistic回归分析提示尿钠排泄增多是高三酰甘油血症的独立危险因素[OR(95%CI):1.006(1.001,1.010),P=0.010]。结论高盐膳食是2型糖尿病患者高三酰甘油血症的重要危险因素,控制钠盐摄入可能有助于改善糖尿病患者血脂紊乱。 Objective To explore the relationship between 24-h urinary sodium and lipid metabolism in patients with type 2 diabetes. Methods Two hundred in-patients with type 2 diabetes were enrolled and 24-h urinary sodium, fasting blood glu- cose and lipid parameters were measured. One-way ANOVA and Logistic regression analysis were performed to investigate the impacts of 24-h urinary sodium on dyslipidemia. Results The subjects were divided into 4 groups according to quartiles of the 24-h urinary sodium. There was an increasing trend in triglycerides among the four groups. The concentration of plas- ma triglyceride was significantly higher in patients with the highest quartile of the 24-h urinary sodium than that with the lowest urinary sodium ( 1.87 [ 1.24 - 3.93] mmol/L vs 1.43[1. 13 - 2. 20 ] mmol/L,P = 0. 015 ). Logistic regression analy- sis showed that 24-h urinary sodium was the independent risk of hyperlipidemia in type 2 diabetes ( OR[ 95% CI] : 1. 006 [ 1. 001,1. 010] ,P = 0. 010). Conclusion High salt intake may be an important risk factor in hypertriglyceridemia and control of sodium intake will prevent dyslipidemia in patients with type 2 diabetes.
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2014年第4期360-363,共4页 Chinese Journal of Practical Internal Medicine
基金 国家重点基础研究发展计划(2012CB517805) 第三军医大学临床医学重大科研项目(2012XLC08) 重庆市科技攻关项目(CSTC2019gg-yyjs10062)
关键词 尿钠 血脂 2型糖尿病 urinary sodium triglyceride type 2 diabetes
  • 相关文献

参考文献13

二级参考文献29

  • 1关悦,乔虹.同型半胱氨酸与糖尿病肾病的相关性研究[J].医学研究生学报,2011,24(5):547-549. 被引量:14
  • 2Waugh N, Cummins E, Royle P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation [ J]. Health Technol Assess, 2010, 14(36) : 1. 被引量:1
  • 3VanDeKoppel S, Choe H M, Sweet B V. Managed care per- spective on three new agents for type 2 diabetes[J]. J Manag Care Pharm, 2008, 14(4) : 363. 被引量:1
  • 4Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al. Saxagliptia given in combination with metformin as initial therapy im- proves glycaemic control in patients with type 2 diabetes com- pared with either monotherapy: a randomized controlled trial [J]. Diabetes Obes Metab, 2009, 11(6) : 611. 被引量:1
  • 5Gake B, Gallwitz B, Eriksson J, et al. Saxagliptin is non-in- ferior to glipizide in patients with type 2 diabetes mellitus in- adequately controlled on metformin alone : a 52-week random- ised controlled trial[ J]. Int J Clin Pract, 2010, 64 (12) : 1619. 被引量:1
  • 6Scirica B M, Bhatt D L, Braunwald E, et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction ( SAVOR-TIMI ) 53 study [ J ]. Am Heart J, 2011, 162(5) : 818. 被引量:1
  • 7Aroda V R, Henry R R, Han J, et al. Efficacy of GLP-1 re- ceptor agonists and DPP-4 inhibitors: meta-analysis and sys- tematic review[J]. Clin Ther, 2012, 34(6): 1247. 被引量:1
  • 8Scheen A J. DPP-4 inhibitors in the management of type 2 di- abetes : a critical review of head-to-head trims [ J ]. Diabetes Metab, 2012, 38(2) : 89. 被引量:1
  • 9Cook W, Bryzinski B, Slater J, et al. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovas- cular disease history or cardiovascular risk factors: Results of a pooled analysis of phase 3 clinical trials[ J]. Postgrad Med, 2013, 125(3): 145. 被引量:1
  • 10Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-nave patients with type 2 diabetes [ J]. Curr Med Res Opin, 2009, 25 (10) : 2401. 被引量:1

共引文献130

同被引文献84

  • 1朱彩平,张声华.枸杞多糖对高脂血症小鼠血脂及脂质过氧化的影响[J].营养学报,2005,27(1):79-80. 被引量:53
  • 2王红英.中药多糖研究进展[J].实用医技杂志,2006,13(6):1021-1022. 被引量:29
  • 3徐兴森,杨万涛,刘道燕,钟健,田志强,闫振成,倪银星,陈静,赵志钢,祝之明.高血压合并代谢紊乱及对心肾血管的影响[J].中华高血压杂志,2006,14(11):894-898. 被引量:52
  • 4王吉彦.拉西地平联合缬沙坦对糖尿病高血压早期肾损害的疗效观察[J].医学信息,2012,24(7):507-508. 被引量:2
  • 5Hou X, Lu J, Weng J, et al. Impact of waist circumference and body mass index on risk of cardiometabolic disorder and cardiovascular disease in Chinese adults: a national diabetes and metabolic disorders survey[J]. PLoS One, 2013, 8(3): e57319. 被引量:1
  • 6Bramlage P, Pittrow D, Wittchen HU, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled[J]. AmJ Hypertens, 2004, 17: 904-910. 被引量:1
  • 7Brown IJt Tzoulaki It Candeias V, et al. Salt intakes around the world: implications for public health[J]. IntJ Epidemiol, 2009, 38(3): 791- 813. 被引量:1
  • 8da Silva AA, do Carmo JM, Hall JE.Role of leptin and central nervous system melanocortins in obesity hypertension[J]. Curr Opin Nephrol Hypertens, 2013, 22(2): 135-140. 被引量:1
  • 9Vankov I, Maletlnskt L, Behuliak M, et al. Obesity-related hypertension: possible pathophysiological mechanisms[J]. J Endocrinol, 2014j 223(3): R63-78. 被引量:1
  • 10Hall JE, Crook ED, Jones DW, et al. Mechanisms of obesity-associated cardiovascular and renal disease[J]. AmJ Med Sci, 2002, 324(3):127- 137. 被引量:1

引证文献8

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部